Popular Articles From: Freeport-McMoRan Reports Third-Quarter and Nine-Month 2014 Results to Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe


Freeport-McMoRan Inc. (NYSE: FCX): Net income attributable to common stock totaled $552 million, $0.53 per share, for third-quarter 2014, compared with net income of $821 million, $0.79 per share, for third-quarter 2013.
Sign-up for Freeport-McMoRan Reports Third-Quarter and Nine-Month 2014 Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978702001&sourceType=1 http://www.ccnmatthews.com/logos/20110815-freeholdroyalites.jpg CALGARY, ALBERTA --
Sign-up for Freehold Royalties Ltd. Announces 2014 Third Quarter Results investment picks
Fred's, Inc. (NASDAQ: FRED) today reported financial results for the third quarter and nine months ended November 1, 2014.
Sign-up for Fred's Reports Third Quarter 2014 Results investment picks
EVANSVILLE, Ind., Oct.
Sign-up for Founders Financial Corporation Shareholders Approve Merger With Old National Bancorp investment picks
Building a diversified producer in a challenging resource market Issued Capital: 194,578,180 LONDON, ON , Nov.
Sign-up for Fortune Minerals provides corporate update and announces third quarter financial results investment picks
Barnes & Noble, Inc. ( NYSE:BKS) , the nation’s largest retail bookseller and the leading retailer of content, digital media and educational products, today announced it has amassed a truly spectacular, largest-of-its-kind signed edition book collection available for in-store customers this Black Friday.
Sign-up for For Black Friday, Barnes & Noble Announces Largest-Ever Signed Edition Offering in Stores: 500,000 Books Signed by More than 100 of the Biggest Authors investment picks
First Trust/Aberdeen Global Opportunity Income Fund (the “Fund”) (NYSE: FAM) has declared a long-term capital gain distribution of $0.11 per share payable on November 17, 2014, to shareholders of record as of November 5, 2014.
Sign-up for First Trust/Aberdeen Global Opportunity Income Fund Declares its Monthly Common Share Distribution of $0.11 Per Share for November investment picks
First Trust MLP and Energy Income Fund (the “Fund”) (NYSE: FEI) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.1117 per share payable on November 17, 2014, to shareholders of record as of November 5, 2014.
Sign-up for First Trust MLP and Energy Income Fund Declares its Monthly Common Share Distribution of $0.1117 Per Share for November investment picks
First Trust Energy Infrastructure Fund (the “Fund”) (NYSE: FIF) has declared the Fund’s regularly scheduled monthly common share distribution of $0.11 per share payable on December 10, 2014 to shareholders of record as of December 3, 2014.
Sign-up for First Trust Energy Infrastructure Fund Declares its Monthly Common Share Distribution of $0.11 per Share for December investment picks
Fiserv , Inc. (NASDAQ: FISV), a leading global provider of financial services technology solutions, announced today that Farmers Insurance Group Federal Credit Union (FIGFCU), based in Los Angeles, has selected the DNA ™ account processing platform and a host of complementary Fiserv solutions as technology cornerstones for its future growth.
Sign-up for Farmers Insurance Group Federal Credit Union Selects DNA and Integrated Surround Solutions from Fiserv investment picks
EXCO Resources, Inc. (NYSE:XCO) (“EXCO”) today closed the previously announced sale of its 25.5% interest in Compass Production Partners, LP and its 50% interest in Compass Production GP, LLC to an affiliate of Harbinger Group, Inc. (NYSE: HRG) (“Harbinger”) for $118.75 million in cash.
Sign-up for EXCO Resources, Inc. Announces Closing of Sale of Interests in Compass Production Partners investment picks
LANCASTER, Ohio, Nov.
Sign-up for EveryWare Global, Inc. Announces Third Quarter 2014 Results investment picks
EVERTEC, Inc. (NYSE: EVTC) (“EVERTEC” or the “Company”) today announced the appointment of Morgan "Mac" Schuessler as President and Chief Executive Officer, and Member of the Board of Directors, effective January 1, 2015.
Sign-up for EVERTEC Announces New CEO investment picks
Evercore Partners Inc. (NYSE:EVR) today announced that it completed on October 31, 2014 the acquisition of the ISI International Strategy & Investment and the remainder of its legacy Institutional Equities business.
Sign-up for Evercore Completes Acquisition of ISI Group investment picks
Essent Group Ltd.
Sign-up for Essent Executive Vice President, Adolfo Marzol, to Retire March 31, 2015 investment picks
EQT Midstream Partners, LP (Partnership) (NYSE: EQM) will host its teleconference with security analysts on October 23, beginning at 11:30 a.m. Eastern Time.
Sign-up for EQT Midstream Partners, LP Announces Q3 2014 Earnings Conference Call investment picks
MIGDAL HA'EMEQ, Israel, Nov.
Sign-up for Enzymotec Ltd. Initiates Clinical Study of Vayarin(R) in Adult ADHD investment picks
Expanding content portfolio leverages integrated media platforms to reach Latino audiences LOS ANGELES , Sept.
Sign-up for Entravision Communications Corporation Launches New Radio Program "LA's Mananitas Morning Show" on Super Estrella 107.1 FM in Los Angeles, CA investment picks
Enphase Energy, Inc. (NASDAQ:ENPH), announced today its participation at the ROTH Capital Partners Solar Symposium in Las Vegas, NV.
Sign-up for Enphase Energy to Host Analyst Day and Participate at ROTH Capital Partners Solar Symposium on October 22, 2014 investment picks
By Tomi Kilgore, MarketWatch Crude oil futures turn higher, but shale-oil producers still getting pounded Energy stocks were in broad decline Monday, as a sharp turn higher in crude oil prices failed to fuel any investor optimism in the recently beaten-down sector.
Sign-up for Energy stocks pummeled again, despite crude's bounce investment picks
- Total quarterly revenues of $764 million, reported diluted (GAAP) loss per share of $1.64 and adjusted diluted EPS of $1.15. - Strong financial results driven by combination of solid growth from the base business and the completion of multiple accretive acquisitions over the past year.
Sign-up for Endo Reports Third Quarter Financial Results investment picks
Endo Announces Launch of Generic Version of Valcyte® Canada NewsWire DUBLIN , Nov.
Sign-up for Endo Announces Launch of Generic Version of Valcyte® investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that 25 abstracts reporting the results of hepatitis C virus (HCV) treatment regimens containing ABT-450, Enanta’s lead protease inhibitor, or ABT-493, Enanta’s next-generation protease inhibitor, have been accepted for presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 7-11, 2014 in Boston, MA.
Sign-up for Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing ABT-450 or ABT-493 to be Presented at the American Association for the Study of Liver Diseases (AASLD) investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie’s investigational, all-oral, interferon-free treatment of VIEKIRAX™ (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA™ (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX™ only, with RBV, for patients with genotype 4 (GT4) HCV infection.
Sign-up for Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Popular Articles From: Freeport-McMoRan Reports Third-Quarter and Nine-Month 2014 Results to Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent